Biosect,
I could be wrong, but I believe that companies who's products were approved in pancreatic cancer had little trouble having their products used in other cancers off label and in further clinical trials those products were found effective in many cancers. Pancreatic cancer was chosen because it's one of the deadliest solid cancers, trials generally don't take that long because patients don't live that long.
I believe much the same can be said for GBM and it's further complicated by the blood-brain barrier. It's clear that are vaccine is working, and in doing so it's also permitting other therapeutics, like Keytruda, to get through the blood-brain barrier that previously were ineffective in GBM trials or treatment. The question is, will the medical community see that it may have tremendous potential in other solid cancers and use it off label, or will they insist on further proof by trials in other solid cancers, possibly including pancreatic, which might be done fairly quickly as life expectancy is so short. Of course with DCVax-L it would have to be on patients who had the Whipple procedure, and they live longer than those with inoperable pancreatic cancer. It might be an excellent candidate for DCVax-Direct as if it's effective when injected right into the tumor it shouldn't take long to know. The few people I've known that had the Whipple have lived a couple years post surgery, I really can't say I know any really long term survivors. We recently lost a friend with it who passed on just a couple months after it was discovered.
Gary
Market Data 
Markets 
AI
